SlideShare a Scribd company logo
1 of 35
1
Mats Sundgren, AstraZeneca
EHR4CR Coordinator
Evolving Evidence: Advancing the
Use of Electronic Health Records for
Clinical Research and
Drug Development
22
Outline
 Problem statement
 The EHR4CR project
 Scaling up towards a pan-European platform supporting clinical
research
 Champion Program with Efpia companies and European hospitals
 Governance via The European Institute for Innovation through Health
Data
3
PROBLEM STATEMENT
44
Problems with clinical trials
The percentage of studies
that complete enrolment
on time:
18% in Europe,
7%in the US1
Almost
50% of all trial
delays caused by patient
recruitment problems2
1/3of protocol
amendments are
avoidable, at a cost
of $0.5m
50%
of today’s clinical
trials fail to
achieve the target
recruitment4
Each day a drug is
delayed from market,
sponsors lose3 up to
$8m
3. Beasley, “Recruiting” 2008
4. Tufts -http://clinicalperformancepartners.com/wp-content/uploads/2012/07/Fixing-
Feasibility-Final-Jan-2012.pdf
1. State of the Clinical Trials Industry: A Sourcebook of Charts and Statistics, Center Watch, 2008.
2. Study Participant Recruitment and Retention in Clinical Trials: Emerging strategies in Europe, the US and Asia,
Business Insights, June 2007.
 Incomplete and delayed clinical trials are a sore spot of drug development
55
There is a need to bridge the gap
We have imagined an environment where de-identified patient data
can be re-used within healthcare and research for clinical research
purposes…
 Across countries
 Across systems
 Across sites
…to speed up protocol
design, patient recruitment,
data capture, safety reporting…
Patient
health records
De-identified
data for Clinical
Research
as a beginning
6
THE PROJECT
6
77
The EHR4CR project
 EHR4CR – Electronic Health Records for Clinical Research
 4+1 year project (2011-2016), 35 partners, budget >17M€
 Objectives & Scope
 Provide a scalable platform for trustworthy re-use of EHR data to
support innovation in clinical research and healthcare operations
 Unlocking Real World Data for optimising clinical trials
 Status
 Extended into 2016 for making the transition to a sustainable
platform
 Initiating a EHR4CR Champion Programme, connecting hospitals to
an operational platform, building up experience with pharma
 Established the European Institute for Innovation through Health
Data – an independent governance body
For more information:
http://www.ehr4cr.eu/
88
The EHR4CR objective
 Research and develop a trustworthy service platform able to unlock clinical information stored in
EHRs for improving clinical research
 Clear focus on three (3) relevant use cases
SAFETY REPORTING
PROTOCOL
FEASIBILITY
PATIENT
RECRUITMENT
DATA
CAPTURE AND
EXCHANGE
Enabling protocol testing with
real world data in potential trial
sites rather than with
guestimates.
Speeding up recruitment by making
EHR data searchable for
investigators and establishing a
unified communication path
between sponsors and sites.
Facilitating EHR data extraction for
applications used during trial
execution (e.g. prefilling of CRFs
and of SAE reports).
9
Brings together key stakeholders
35 participants
including
pharmaceutical
industry, academia ,
hospitals, SMEs, patient
associations and public
authorities
11 hospital
sites
10 Pharma
Companies
Advisory
boards and
other
experts
1010
Status of the EHR4CR project…
EHR4CR - IMI
research project
Operational pan-
European platform
Pilot hospitals
 11 major hospitals in 5
countries.
 Germany (WWU, FAU)
 France (AP-HP, U936)
 UK (UoD, UoG, UoM, UCL, KCL)
 Switzerland (HUG)
 Poland (MuW)
Scaling up the
solutions!
 Technology
 Operations
 Governance
 Sustainability
Operational pan-European platform
 EHR4CR Champion Program
 Permanent network of clinical sites
giving access to millions of patients in
close to real time
 Trial design and recruitment supported
by real-world evidence on a European
scale
 Governance by the with European
Institute for Innovation through Health
Data
Project pilots
 Feasibility & Recruitment
 12 studies, different
therapeutic areas
 De-identified data from
>500k patients over 11 sites
11
THE PLATFORM AND
SERVICES
1212
The EHR4CR platform
Semantic
interop.
Security
AuthN
AuthZ
Audit
Workflow
Messaging
Platform
Management
Terminology
Services
Mapping
...Local
Applications
ETL
Site dependent
process
Application
Services
Centrally deployed
(Saas/Paas)
(Virtual)
appliance
NO patient
data leaves
the hospitals!
1313
The EHR4CR platform – dataflow
Recruitment
Workbench
Central
Feasibility &
Recruitment
Workbench
ETL
Trial
Candidates
<< Queries
#Counts >>
#Counts >>
Enabled
<< Clinical Trial
Recruitment Progress >>
Recruitment Progress >>
EHR4CR PLATFORMHOSPITAL/DATA PROVIDER RESEARCH CENTRE
e.g. pharmaceutical company
Protocol feasibility service
Patient recruitment service
1414
Evolution towards a mature platform service
EHR4CR proof
of concept
Custodix commits to being an
EHR4CR service & platform provider
Other know-how &
experiences
EHR4CR proof
of concept
Other know-how &
experiences
1515
Protocol Feasibility workflow (study design)
Design study
(formalize
criteria)
Execute
(automated)
Central Platform
Clinical Site
9
2
5
Select sites of
interest
Launch queries
(test study)
Report
results
6
Analyze results
73 4
1
8
1616
Patient identification & recruitment workflow
Formalize
the trial
criteria
Invite Sites
of interest
Accept study
participation
Fine tune
formalized
eligibility
criteria
Launch trial
at Site
Track
progress
Review
suggested
candidate
patients
After identification,
eligible patients
can be contacted.
If they consent to
the study, they can
be registered in
the trial through
the existing
processes.
Central Platform
Clinical Site
3
1
2 6 9
4 5 7
8
1717
InSite Clinical Platform – overview
Patient Identification
and Recruitment
Service
Protocol Feasibility
Service
Site
Management
Central Platform
Cohort selection and
analysis tool
Computer assisted
patient recruitment
application
Site Services
Installed and used inside the hospital
Central service
available to
researchers
1818
InSite central platform screenshot
PFS Authoring criteria (queries)
Clinical concept quick
search
Clinical concepts to
design queries with
(ICD, LOINC,
SNOMED, etc.)
Designing feasibility queries (i.e. eligibility criteria )
1919
InSite central platform screenshot
PFS viewing results
Country summary
Site summary
20
SCALING UP: TOWARDS A
PAN-EUROPEAN PLATFORM
SUPPORTING CLINICAL
RESEARCH
20
2121
2015 – 2016 Champion Programme
The Champion Programme serves to:
 Further validate and improve technology
 Define (refine) the rules of engagement
for a sustainable ecosystem
 Start building a network of hospitals
 Engage with European Institute for
Innovation through Health Data which
aims to govern the EU data re-use
ecosystem
“A multi-stakeholder collaboration
aiming to accelerate and ensure the
future of clinical research in Europe.”
Targeting hospitals in
Belgium, Germany,
Finland, France,
Italy, Netherlands,
Poland, Spain,
Switzerland, Sweden,
and US
2222
Value for pharma & research organisations
Clear value proposition for research organisations
Better trial design
 Optimising clinical protocol design will reduce costly
corrective measures such as protocol amendments, late
addition of new trial countries or sites.
Quicker achieved recruitment targets
 Computer assisted patient identification tools result in
accelerated identification, fewer patients missed,…
Increase revenue
 The platform will reduce the elapsed clinical trial time, which in the
end translates into a quicker time to market and thus additional
revenue (increased time on market under patent protection).
Reduce cost
 Less manual work, less corrective measures, etc. lead automatically
to a decrease in total trial cost. Pharma will also avoid the expense
and time and effort of opening trial sites which will not yield enough
patients.
Overall increased efficiency
 Further automation and optimisation of the clinical trial
process by use of a central platform result in an overall
increased efficiency.
Improve trial success rate
 The number of trials failed due to failure to recruit will be
reduced.
2323
Better quality data
The clinical trial platform stimulates
hospitals to focus on the quality of
their data. Improved monitoring,
performance benchmarking,
reporting and management (e.g.
reimbursement coding) drives
optimization of patient care and
improved internal management.
Enhanced reputation
Hospitals and their physicians
participating in more clinical
trials will get greater visibility
in scientific community.
Which on its turn will attract
more research (trials), top-
class physicians and more
patients (once reputation gets
picked up by the media).
Better patient care
More patients will get access
to trial drugs and
innovative care pathways at
no additional cost to the
hospital.
Physicians participating in
clinical trial are in general
more up to date with medical
science.
Increased income
Cutting cost will no longer be
sufficient to deal with the
overall healthcare budget
decrease. Hospitals need to
search for new revenue
streams, the clinical trial
platform will help them to
attract more trials and thus
income.
Value for hospitals
Access to tools
Participation to the clinical trial
platform includes free access to
a set of tools to explore and
analyze patient data.
Anyone familiar with the cost of
clinical IT systems understands
the value of this benefit.
Value generated at multiple levels: clinical research, overall care provision and revenue
24
THE GOVERNANCE
25 2
5
The European Institute for Innovation through Health Data (i~HD)
has been formed as one of the key sustainable entities arising from the EHR4CR and
SemanticHealthNet projects, in collaboration with several other European projects and initiatives
supported by the European Commission
i~HD is registered in Belgium
as a not-for-profit organisation
It is being financed by membership fees,
by providing services
such as certification and governance and through
specifically-funded projects and initiatives
Guiding and catalysing the best, most efficient and trustworthy
uses of health data and interoperability,
for optimising health and knowledge discovery
www.i-hd.eu
26
i~HD has been formed because a complementary, neutral and
not-for-profit organisation is needed
 to play a central role in governing and expanding a trustworthy health
data driven ecosystem including EHRs and EHR4CR platform services
 to promote the adoption of healthcare standards and of data
quality, to enable more effective, safer and better integrated healthcare
 to act as a connector between health care and clinical research
standards, that are presently developed in silos and impair the
interoperability and pooling of health data for research
 to promote to society the importance of using health data for
research, to improve efficiency through reduced duplications, delays,
costs enhance speed and efficiency in clinical studies
Ensuring the trustworthy reuse of health data for research
2
7
Segregation…
of the research data
warehouse from the
hospital EHR De-identification…
individual patient data are de-
identifed
Control…
lock/unlock access by
hospital
Consolidation…
only aggregated patient
numbers leave the hospital
Governance…
independent institute ensures
data are accessed in a
trustworthy way
Governing the EHR4CR ecosystem
Educate and train
research and ICT staff
Accredit staff
and organisations
Certify service
providers
and EHR systems
Oversee and audit
governance & security
EHR4CR
SERVICE
PROVIDER
LOCAL PROVIDERS
SERVICE
USER
PLATFORM
PROVIDER
SERVICE
USER
OTHER DATA
AGGREGATORS
DATA PROVIDER
RESEARCH
SPONSOR
RESEARCH
SPONSOR
DATA PROVIDER
ICT SOLUTION PROVIDERS RESEARCH
ORGANISATIONS
LOCAL
PROVIDERS
The needs…
29
i~HD will
 provide an essential governance framework for the scale up of EHR4CR and
future research platforms across Europe
 certifying research platforms and service providers
 establishing codes of practice and privacy protection policies
 conducting audits and investigating any concerns about security and privacy
 educating the public of the value of using health data for research and
assuring them about the governance protecting their privacy
 support better quality and interoperability of health data
 establishing a Network of Excellence amongst data providers to improve data quality
 identifying ICT mature data sources e.g. hospitals
 facilitating alignment amongst standards bodies, especially in semantic interoperability,
ensuring that future standards prioritise clinical and research needs
2
9
30
CLOSER LOOK AT
CHAMPION PROGRAM
3131
Long term objective
 Establish a network of clinical sites able to quickly engage into clinical research
 Connect clinical sites to the clinical platform bringing them in close contact with EFPIA
companies and CROs
 Empower clinical sites to support clinical trial processes through locally provided technology
 Computer assisted recruitment, extraction of EHR-data for reporting (eCRF, SAE, …), cohort analysis,
etc.
 Provide a multitude of services to optimise internal clinical trial processes through data
re-use, freeing up time for care & research
 Protocol feasibility, patient recruitment, EHR data extraction, eCRF and report pre-filling, etc.
3232
Initial services
Protocol feasibility / Trial
Design services
 Optimise protocol eligibility
criteria by instantaneously
testing them out in multiple sites
in various countries
 Directly identify the countries
and specific sites to approach
for participation
Trial recruitment services
• Distribute trial protocols over
multiple sites in a uniform way
• Track recruitment progress in
real time
• Optimal recruitment due to
tools provided to hospitals
Starting with a simple
service offering for
Research Organisations
 Initial focus is on building the
network and introducing the
technology in hospitals
 The two services should be able
to demonstrate the value of this
initiative to all stakeholders
 Piloting new services will be
done as the need arises
 The service offering will be
expanding as the technology
matures
3333
Efpia Champion Programme summary
The Champion Programme is designed to provide a low-risk entry for all stakeholders into this innovative approach to efficient use of
Real World Data. It is a key step in building the EHR4CR envisaged ecosystem of network of hospitals, service providers and pharma
users.
 Objectives
 Validating and further improving the platform together with Custodix (first Service and Platform Provider) by connecting 15-30
hospitals during 2015-2016.
 Define (refine) the rules of engagement for a sustainable ecosystem (including defining the governance role of the European
Institute of Innovation in Health Data).
 Scope
 Evaluate platform services for Protocol Feasibility, Patient Identification & Recruitment across multiple therapeutic areas (TAs)
with a broad geographical coverage in Europe and reaching out to the US.
 Outcome
 A proven ecosystem for acceleration of clinical research through Real World Data, ready to further expand geographically
and data source wise (registries, research data bases, PHR, mHealth apps data, …)
 Status
 7 EFPIA Champion companies (Amgen, AZ, Bayer, GSK, Janssen, Roche, Sanofi) constitute the core Efpia Champions
 Initiation autumn 2015
3434
The EHR4CR project is an important initiative
 Bringing together multiple
stakeholders
 Overcoming barriers that limit
access to EHRs for research
 Developing a platform and
services for trustworthy re-use of
EHR data within and outside
Europe
Patient
health records
Clinical
researcher
De-identified
data for
Clinical
Research
www.insiteplatform.com
35
Thank You! Contact us:
comms@ehr4cr.eu
European Institute for Innovation
Through Health Data
www.i-hd.eu
Custodix InSite Platform
www.insiteplatform.com

More Related Content

What's hot

Clinical Trial Registries
Clinical Trial RegistriesClinical Trial Registries
Clinical Trial RegistriesMichael Swit
 
GXP Inspection readiness
GXP Inspection readinessGXP Inspection readiness
GXP Inspection readinessArete-Zoe, LLC
 
Globalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataGlobalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataAnnet Visscher
 
Tga presentation National Medicines Symposium 19 may 2016
Tga presentation National Medicines Symposium 19 may 2016Tga presentation National Medicines Symposium 19 may 2016
Tga presentation National Medicines Symposium 19 may 2016TGA Australia
 
EU Clinical Investigations Taipei 2018
EU Clinical Investigations Taipei 2018EU Clinical Investigations Taipei 2018
EU Clinical Investigations Taipei 2018Annet Visscher
 
Cortellis for Clinical Trials Intelligence Large Group Training
Cortellis for Clinical Trials Intelligence Large Group TrainingCortellis for Clinical Trials Intelligence Large Group Training
Cortellis for Clinical Trials Intelligence Large Group TrainingMichael Passanante
 
Flow Cytometry 2012: Market Needs, Emerging Developments and Future Use
Flow Cytometry 2012: Market Needs, Emerging Developments and Future UseFlow Cytometry 2012: Market Needs, Emerging Developments and Future Use
Flow Cytometry 2012: Market Needs, Emerging Developments and Future UseReportsnReports
 
Importance of systematic literature search for clinical evaluation (CE) the s...
Importance of systematic literature search for clinical evaluation (CE) the s...Importance of systematic literature search for clinical evaluation (CE) the s...
Importance of systematic literature search for clinical evaluation (CE) the s...PEPGRA Healthcare
 
Edith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation ConferenceEdith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation ConferenceStarttech Ventures
 
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the VeilClinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the VeilJulia Kondakov
 
Clinical trial registration: where & why ?
Clinical trial registration: where &  why  ?Clinical trial registration: where &  why  ?
Clinical trial registration: where & why ?Ahmed-Refat Refat
 
Point of Care Diagnostics: Revenue Growth, New Entrants, Investment
Point of Care Diagnostics: Revenue Growth, New Entrants, InvestmentPoint of Care Diagnostics: Revenue Growth, New Entrants, Investment
Point of Care Diagnostics: Revenue Growth, New Entrants, InvestmentBruce Carlson
 
Presentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical DevicesPresentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical DevicesTGA Australia
 
Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016
Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016 Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016
Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016 ipposi
 
Clinical Trials Registry
Clinical Trials RegistryClinical Trials Registry
Clinical Trials Registrybiinoida
 
Regulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaRegulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaTGA Australia
 
BOORSTEIN.tue_.4pm.Final_
BOORSTEIN.tue_.4pm.Final_BOORSTEIN.tue_.4pm.Final_
BOORSTEIN.tue_.4pm.Final_Hidee Cyd
 

What's hot (20)

Clinical Trial Registries
Clinical Trial RegistriesClinical Trial Registries
Clinical Trial Registries
 
Clinical Trial Primer
Clinical Trial PrimerClinical Trial Primer
Clinical Trial Primer
 
GXP Inspection readiness
GXP Inspection readinessGXP Inspection readiness
GXP Inspection readiness
 
WHODrug as linked data
WHODrug as linked dataWHODrug as linked data
WHODrug as linked data
 
Globalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataGlobalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device data
 
Tga presentation National Medicines Symposium 19 may 2016
Tga presentation National Medicines Symposium 19 may 2016Tga presentation National Medicines Symposium 19 may 2016
Tga presentation National Medicines Symposium 19 may 2016
 
EU Clinical Investigations Taipei 2018
EU Clinical Investigations Taipei 2018EU Clinical Investigations Taipei 2018
EU Clinical Investigations Taipei 2018
 
Cortellis for Clinical Trials Intelligence Large Group Training
Cortellis for Clinical Trials Intelligence Large Group TrainingCortellis for Clinical Trials Intelligence Large Group Training
Cortellis for Clinical Trials Intelligence Large Group Training
 
Ctri
CtriCtri
Ctri
 
Flow Cytometry 2012: Market Needs, Emerging Developments and Future Use
Flow Cytometry 2012: Market Needs, Emerging Developments and Future UseFlow Cytometry 2012: Market Needs, Emerging Developments and Future Use
Flow Cytometry 2012: Market Needs, Emerging Developments and Future Use
 
Importance of systematic literature search for clinical evaluation (CE) the s...
Importance of systematic literature search for clinical evaluation (CE) the s...Importance of systematic literature search for clinical evaluation (CE) the s...
Importance of systematic literature search for clinical evaluation (CE) the s...
 
Edith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation ConferenceEdith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation Conference
 
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the VeilClinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
Clinical Trial Opportunities in Russia and Eastern Europe - Raising the Veil
 
Clinical trial registration: where & why ?
Clinical trial registration: where &  why  ?Clinical trial registration: where &  why  ?
Clinical trial registration: where & why ?
 
Point of Care Diagnostics: Revenue Growth, New Entrants, Investment
Point of Care Diagnostics: Revenue Growth, New Entrants, InvestmentPoint of Care Diagnostics: Revenue Growth, New Entrants, Investment
Point of Care Diagnostics: Revenue Growth, New Entrants, Investment
 
Presentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical DevicesPresentation: Draft Clinical Evidence Guidelines – Medical Devices
Presentation: Draft Clinical Evidence Guidelines – Medical Devices
 
Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016
Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016 Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016
Clinical Research Training - Dr Ruben Keane, UCC - Dec 7th 2016
 
Clinical Trials Registry
Clinical Trials RegistryClinical Trials Registry
Clinical Trials Registry
 
Regulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaRegulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in Australia
 
BOORSTEIN.tue_.4pm.Final_
BOORSTEIN.tue_.4pm.Final_BOORSTEIN.tue_.4pm.Final_
BOORSTEIN.tue_.4pm.Final_
 

Similar to Evoulution Summit_November_2015_Sundgren

Professor Dipak Kalra Digital Health Assembly 2015
Professor Dipak Kalra Digital Health Assembly 2015Professor Dipak Kalra Digital Health Assembly 2015
Professor Dipak Kalra Digital Health Assembly 2015DHA2015
 
Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015GBX Events
 
CURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM SymposiumCURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM SymposiumMelanoma Research Foundation
 
Clinical trial recruitment overview
Clinical trial recruitment overviewClinical trial recruitment overview
Clinical trial recruitment overviewUsama Malik
 
Big data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleBig data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
 
Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...
Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...
Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...Wes Wheeler
 
Clinical Trial Registration
Clinical Trial RegistrationClinical Trial Registration
Clinical Trial RegistrationPallav Singhal
 
Multifactorial Approach in Clinical Research Concept and Practice in Hungary
Multifactorial Approach in Clinical Research Concept and Practice in HungaryMultifactorial Approach in Clinical Research Concept and Practice in Hungary
Multifactorial Approach in Clinical Research Concept and Practice in HungaryTristan Azbej, PhD
 
The Top 5 Ancillary Services For Urology Practices
The Top 5 Ancillary Services For Urology PracticesThe Top 5 Ancillary Services For Urology Practices
The Top 5 Ancillary Services For Urology PracticesClark Love
 
Innovative Hospital Partnership Model for High Quality Patient Clinical Trials
Innovative Hospital Partnership Model for High Quality Patient Clinical TrialsInnovative Hospital Partnership Model for High Quality Patient Clinical Trials
Innovative Hospital Partnership Model for High Quality Patient Clinical TrialsSGS
 
Patientory and its Role in Clinical Trials Transparency
Patientory and its Role in Clinical Trials TransparencyPatientory and its Role in Clinical Trials Transparency
Patientory and its Role in Clinical Trials TransparencyPatientory
 
How to Make Postmarket Surveillance More Cost Effective
How to Make Postmarket Surveillance More Cost EffectiveHow to Make Postmarket Surveillance More Cost Effective
How to Make Postmarket Surveillance More Cost EffectiveApril Bright
 
Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...
Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...
Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...CRF Health
 
NI Electronic Care Record - Des O'Loan
NI Electronic Care Record - Des O'LoanNI Electronic Care Record - Des O'Loan
NI Electronic Care Record - Des O'Loanhealthcareisi
 

Similar to Evoulution Summit_November_2015_Sundgren (20)

Professor Dipak Kalra Digital Health Assembly 2015
Professor Dipak Kalra Digital Health Assembly 2015Professor Dipak Kalra Digital Health Assembly 2015
Professor Dipak Kalra Digital Health Assembly 2015
 
Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015
 
0107 Jan Geissler - How drug development works and elements of trial protocols
0107 Jan Geissler - How drug development works and elements of trial protocols0107 Jan Geissler - How drug development works and elements of trial protocols
0107 Jan Geissler - How drug development works and elements of trial protocols
 
Chapter 5: The future
Chapter 5: The futureChapter 5: The future
Chapter 5: The future
 
CURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM SymposiumCURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM Symposium
 
Clinical trial recruitment overview
Clinical trial recruitment overviewClinical trial recruitment overview
Clinical trial recruitment overview
 
Big data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleBig data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simple
 
Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...
Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...
Pharma Almanac Q1 2016 Clinical Logistics - Meeting the 21st Century Cures Ch...
 
Clinical Trial Registration
Clinical Trial RegistrationClinical Trial Registration
Clinical Trial Registration
 
Multifactorial Approach in Clinical Research Concept and Practice in Hungary
Multifactorial Approach in Clinical Research Concept and Practice in HungaryMultifactorial Approach in Clinical Research Concept and Practice in Hungary
Multifactorial Approach in Clinical Research Concept and Practice in Hungary
 
Jornadas #PatientInHTA · Jesús González
Jornadas #PatientInHTA · Jesús GonzálezJornadas #PatientInHTA · Jesús González
Jornadas #PatientInHTA · Jesús González
 
What lies ahead for india
What lies ahead for indiaWhat lies ahead for india
What lies ahead for india
 
The Top 5 Ancillary Services For Urology Practices
The Top 5 Ancillary Services For Urology PracticesThe Top 5 Ancillary Services For Urology Practices
The Top 5 Ancillary Services For Urology Practices
 
Sharing Knowledge - Lab outsourcing/Managemeent
Sharing Knowledge - Lab outsourcing/ManagemeentSharing Knowledge - Lab outsourcing/Managemeent
Sharing Knowledge - Lab outsourcing/Managemeent
 
Innovative Hospital Partnership Model for High Quality Patient Clinical Trials
Innovative Hospital Partnership Model for High Quality Patient Clinical TrialsInnovative Hospital Partnership Model for High Quality Patient Clinical Trials
Innovative Hospital Partnership Model for High Quality Patient Clinical Trials
 
Patientory and its Role in Clinical Trials Transparency
Patientory and its Role in Clinical Trials TransparencyPatientory and its Role in Clinical Trials Transparency
Patientory and its Role in Clinical Trials Transparency
 
How to Make Postmarket Surveillance More Cost Effective
How to Make Postmarket Surveillance More Cost EffectiveHow to Make Postmarket Surveillance More Cost Effective
How to Make Postmarket Surveillance More Cost Effective
 
Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...
Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...
Case Study: World's Largest COPD eCOA Trial Requires Reliability and Global S...
 
NI Electronic Care Record - Des O'Loan
NI Electronic Care Record - Des O'LoanNI Electronic Care Record - Des O'Loan
NI Electronic Care Record - Des O'Loan
 
Rodney POC
Rodney POCRodney POC
Rodney POC
 

Evoulution Summit_November_2015_Sundgren

  • 1. 1 Mats Sundgren, AstraZeneca EHR4CR Coordinator Evolving Evidence: Advancing the Use of Electronic Health Records for Clinical Research and Drug Development
  • 2. 22 Outline  Problem statement  The EHR4CR project  Scaling up towards a pan-European platform supporting clinical research  Champion Program with Efpia companies and European hospitals  Governance via The European Institute for Innovation through Health Data
  • 4. 44 Problems with clinical trials The percentage of studies that complete enrolment on time: 18% in Europe, 7%in the US1 Almost 50% of all trial delays caused by patient recruitment problems2 1/3of protocol amendments are avoidable, at a cost of $0.5m 50% of today’s clinical trials fail to achieve the target recruitment4 Each day a drug is delayed from market, sponsors lose3 up to $8m 3. Beasley, “Recruiting” 2008 4. Tufts -http://clinicalperformancepartners.com/wp-content/uploads/2012/07/Fixing- Feasibility-Final-Jan-2012.pdf 1. State of the Clinical Trials Industry: A Sourcebook of Charts and Statistics, Center Watch, 2008. 2. Study Participant Recruitment and Retention in Clinical Trials: Emerging strategies in Europe, the US and Asia, Business Insights, June 2007.  Incomplete and delayed clinical trials are a sore spot of drug development
  • 5. 55 There is a need to bridge the gap We have imagined an environment where de-identified patient data can be re-used within healthcare and research for clinical research purposes…  Across countries  Across systems  Across sites …to speed up protocol design, patient recruitment, data capture, safety reporting… Patient health records De-identified data for Clinical Research as a beginning
  • 7. 77 The EHR4CR project  EHR4CR – Electronic Health Records for Clinical Research  4+1 year project (2011-2016), 35 partners, budget >17M€  Objectives & Scope  Provide a scalable platform for trustworthy re-use of EHR data to support innovation in clinical research and healthcare operations  Unlocking Real World Data for optimising clinical trials  Status  Extended into 2016 for making the transition to a sustainable platform  Initiating a EHR4CR Champion Programme, connecting hospitals to an operational platform, building up experience with pharma  Established the European Institute for Innovation through Health Data – an independent governance body For more information: http://www.ehr4cr.eu/
  • 8. 88 The EHR4CR objective  Research and develop a trustworthy service platform able to unlock clinical information stored in EHRs for improving clinical research  Clear focus on three (3) relevant use cases SAFETY REPORTING PROTOCOL FEASIBILITY PATIENT RECRUITMENT DATA CAPTURE AND EXCHANGE Enabling protocol testing with real world data in potential trial sites rather than with guestimates. Speeding up recruitment by making EHR data searchable for investigators and establishing a unified communication path between sponsors and sites. Facilitating EHR data extraction for applications used during trial execution (e.g. prefilling of CRFs and of SAE reports).
  • 9. 9 Brings together key stakeholders 35 participants including pharmaceutical industry, academia , hospitals, SMEs, patient associations and public authorities 11 hospital sites 10 Pharma Companies Advisory boards and other experts
  • 10. 1010 Status of the EHR4CR project… EHR4CR - IMI research project Operational pan- European platform Pilot hospitals  11 major hospitals in 5 countries.  Germany (WWU, FAU)  France (AP-HP, U936)  UK (UoD, UoG, UoM, UCL, KCL)  Switzerland (HUG)  Poland (MuW) Scaling up the solutions!  Technology  Operations  Governance  Sustainability Operational pan-European platform  EHR4CR Champion Program  Permanent network of clinical sites giving access to millions of patients in close to real time  Trial design and recruitment supported by real-world evidence on a European scale  Governance by the with European Institute for Innovation through Health Data Project pilots  Feasibility & Recruitment  12 studies, different therapeutic areas  De-identified data from >500k patients over 11 sites
  • 12. 1212 The EHR4CR platform Semantic interop. Security AuthN AuthZ Audit Workflow Messaging Platform Management Terminology Services Mapping ...Local Applications ETL Site dependent process Application Services Centrally deployed (Saas/Paas) (Virtual) appliance NO patient data leaves the hospitals!
  • 13. 1313 The EHR4CR platform – dataflow Recruitment Workbench Central Feasibility & Recruitment Workbench ETL Trial Candidates << Queries #Counts >> #Counts >> Enabled << Clinical Trial Recruitment Progress >> Recruitment Progress >> EHR4CR PLATFORMHOSPITAL/DATA PROVIDER RESEARCH CENTRE e.g. pharmaceutical company Protocol feasibility service Patient recruitment service
  • 14. 1414 Evolution towards a mature platform service EHR4CR proof of concept Custodix commits to being an EHR4CR service & platform provider Other know-how & experiences EHR4CR proof of concept Other know-how & experiences
  • 15. 1515 Protocol Feasibility workflow (study design) Design study (formalize criteria) Execute (automated) Central Platform Clinical Site 9 2 5 Select sites of interest Launch queries (test study) Report results 6 Analyze results 73 4 1 8
  • 16. 1616 Patient identification & recruitment workflow Formalize the trial criteria Invite Sites of interest Accept study participation Fine tune formalized eligibility criteria Launch trial at Site Track progress Review suggested candidate patients After identification, eligible patients can be contacted. If they consent to the study, they can be registered in the trial through the existing processes. Central Platform Clinical Site 3 1 2 6 9 4 5 7 8
  • 17. 1717 InSite Clinical Platform – overview Patient Identification and Recruitment Service Protocol Feasibility Service Site Management Central Platform Cohort selection and analysis tool Computer assisted patient recruitment application Site Services Installed and used inside the hospital Central service available to researchers
  • 18. 1818 InSite central platform screenshot PFS Authoring criteria (queries) Clinical concept quick search Clinical concepts to design queries with (ICD, LOINC, SNOMED, etc.) Designing feasibility queries (i.e. eligibility criteria )
  • 19. 1919 InSite central platform screenshot PFS viewing results Country summary Site summary
  • 20. 20 SCALING UP: TOWARDS A PAN-EUROPEAN PLATFORM SUPPORTING CLINICAL RESEARCH 20
  • 21. 2121 2015 – 2016 Champion Programme The Champion Programme serves to:  Further validate and improve technology  Define (refine) the rules of engagement for a sustainable ecosystem  Start building a network of hospitals  Engage with European Institute for Innovation through Health Data which aims to govern the EU data re-use ecosystem “A multi-stakeholder collaboration aiming to accelerate and ensure the future of clinical research in Europe.” Targeting hospitals in Belgium, Germany, Finland, France, Italy, Netherlands, Poland, Spain, Switzerland, Sweden, and US
  • 22. 2222 Value for pharma & research organisations Clear value proposition for research organisations Better trial design  Optimising clinical protocol design will reduce costly corrective measures such as protocol amendments, late addition of new trial countries or sites. Quicker achieved recruitment targets  Computer assisted patient identification tools result in accelerated identification, fewer patients missed,… Increase revenue  The platform will reduce the elapsed clinical trial time, which in the end translates into a quicker time to market and thus additional revenue (increased time on market under patent protection). Reduce cost  Less manual work, less corrective measures, etc. lead automatically to a decrease in total trial cost. Pharma will also avoid the expense and time and effort of opening trial sites which will not yield enough patients. Overall increased efficiency  Further automation and optimisation of the clinical trial process by use of a central platform result in an overall increased efficiency. Improve trial success rate  The number of trials failed due to failure to recruit will be reduced.
  • 23. 2323 Better quality data The clinical trial platform stimulates hospitals to focus on the quality of their data. Improved monitoring, performance benchmarking, reporting and management (e.g. reimbursement coding) drives optimization of patient care and improved internal management. Enhanced reputation Hospitals and their physicians participating in more clinical trials will get greater visibility in scientific community. Which on its turn will attract more research (trials), top- class physicians and more patients (once reputation gets picked up by the media). Better patient care More patients will get access to trial drugs and innovative care pathways at no additional cost to the hospital. Physicians participating in clinical trial are in general more up to date with medical science. Increased income Cutting cost will no longer be sufficient to deal with the overall healthcare budget decrease. Hospitals need to search for new revenue streams, the clinical trial platform will help them to attract more trials and thus income. Value for hospitals Access to tools Participation to the clinical trial platform includes free access to a set of tools to explore and analyze patient data. Anyone familiar with the cost of clinical IT systems understands the value of this benefit. Value generated at multiple levels: clinical research, overall care provision and revenue
  • 25. 25 2 5 The European Institute for Innovation through Health Data (i~HD) has been formed as one of the key sustainable entities arising from the EHR4CR and SemanticHealthNet projects, in collaboration with several other European projects and initiatives supported by the European Commission i~HD is registered in Belgium as a not-for-profit organisation It is being financed by membership fees, by providing services such as certification and governance and through specifically-funded projects and initiatives Guiding and catalysing the best, most efficient and trustworthy uses of health data and interoperability, for optimising health and knowledge discovery www.i-hd.eu
  • 26. 26 i~HD has been formed because a complementary, neutral and not-for-profit organisation is needed  to play a central role in governing and expanding a trustworthy health data driven ecosystem including EHRs and EHR4CR platform services  to promote the adoption of healthcare standards and of data quality, to enable more effective, safer and better integrated healthcare  to act as a connector between health care and clinical research standards, that are presently developed in silos and impair the interoperability and pooling of health data for research  to promote to society the importance of using health data for research, to improve efficiency through reduced duplications, delays, costs enhance speed and efficiency in clinical studies
  • 27. Ensuring the trustworthy reuse of health data for research 2 7 Segregation… of the research data warehouse from the hospital EHR De-identification… individual patient data are de- identifed Control… lock/unlock access by hospital Consolidation… only aggregated patient numbers leave the hospital Governance… independent institute ensures data are accessed in a trustworthy way
  • 28. Governing the EHR4CR ecosystem Educate and train research and ICT staff Accredit staff and organisations Certify service providers and EHR systems Oversee and audit governance & security EHR4CR SERVICE PROVIDER LOCAL PROVIDERS SERVICE USER PLATFORM PROVIDER SERVICE USER OTHER DATA AGGREGATORS DATA PROVIDER RESEARCH SPONSOR RESEARCH SPONSOR DATA PROVIDER ICT SOLUTION PROVIDERS RESEARCH ORGANISATIONS LOCAL PROVIDERS The needs…
  • 29. 29 i~HD will  provide an essential governance framework for the scale up of EHR4CR and future research platforms across Europe  certifying research platforms and service providers  establishing codes of practice and privacy protection policies  conducting audits and investigating any concerns about security and privacy  educating the public of the value of using health data for research and assuring them about the governance protecting their privacy  support better quality and interoperability of health data  establishing a Network of Excellence amongst data providers to improve data quality  identifying ICT mature data sources e.g. hospitals  facilitating alignment amongst standards bodies, especially in semantic interoperability, ensuring that future standards prioritise clinical and research needs 2 9
  • 31. 3131 Long term objective  Establish a network of clinical sites able to quickly engage into clinical research  Connect clinical sites to the clinical platform bringing them in close contact with EFPIA companies and CROs  Empower clinical sites to support clinical trial processes through locally provided technology  Computer assisted recruitment, extraction of EHR-data for reporting (eCRF, SAE, …), cohort analysis, etc.  Provide a multitude of services to optimise internal clinical trial processes through data re-use, freeing up time for care & research  Protocol feasibility, patient recruitment, EHR data extraction, eCRF and report pre-filling, etc.
  • 32. 3232 Initial services Protocol feasibility / Trial Design services  Optimise protocol eligibility criteria by instantaneously testing them out in multiple sites in various countries  Directly identify the countries and specific sites to approach for participation Trial recruitment services • Distribute trial protocols over multiple sites in a uniform way • Track recruitment progress in real time • Optimal recruitment due to tools provided to hospitals Starting with a simple service offering for Research Organisations  Initial focus is on building the network and introducing the technology in hospitals  The two services should be able to demonstrate the value of this initiative to all stakeholders  Piloting new services will be done as the need arises  The service offering will be expanding as the technology matures
  • 33. 3333 Efpia Champion Programme summary The Champion Programme is designed to provide a low-risk entry for all stakeholders into this innovative approach to efficient use of Real World Data. It is a key step in building the EHR4CR envisaged ecosystem of network of hospitals, service providers and pharma users.  Objectives  Validating and further improving the platform together with Custodix (first Service and Platform Provider) by connecting 15-30 hospitals during 2015-2016.  Define (refine) the rules of engagement for a sustainable ecosystem (including defining the governance role of the European Institute of Innovation in Health Data).  Scope  Evaluate platform services for Protocol Feasibility, Patient Identification & Recruitment across multiple therapeutic areas (TAs) with a broad geographical coverage in Europe and reaching out to the US.  Outcome  A proven ecosystem for acceleration of clinical research through Real World Data, ready to further expand geographically and data source wise (registries, research data bases, PHR, mHealth apps data, …)  Status  7 EFPIA Champion companies (Amgen, AZ, Bayer, GSK, Janssen, Roche, Sanofi) constitute the core Efpia Champions  Initiation autumn 2015
  • 34. 3434 The EHR4CR project is an important initiative  Bringing together multiple stakeholders  Overcoming barriers that limit access to EHRs for research  Developing a platform and services for trustworthy re-use of EHR data within and outside Europe Patient health records Clinical researcher De-identified data for Clinical Research www.insiteplatform.com
  • 35. 35 Thank You! Contact us: comms@ehr4cr.eu European Institute for Innovation Through Health Data www.i-hd.eu Custodix InSite Platform www.insiteplatform.com

Editor's Notes

  1. Potentiale der Nutzung elektronischer Patienteninformationen für die klinische Forschung in der Pharmaindustrie -> Potentials of the use of electronic patient information for clinical research in the pharmaceutical industry Replace Towards a new European platform of trustworthy reuse of health data for research: The EHR4CR project
  2. In computing, Extract, Transform and Load (ETL) refers to a process in database usage and especially in data warehousing that: Extracts data from homogeneous or heterogeneous data sources Transforms the data for storing it in proper format or structure for querying and analysis purpose Loads it into the final target (database, more specifically, operational data store, data mart, or data warehouse)